
TMCI Stock Forecast & Price Target
TMCI Analyst Ratings
Bulls say
Treace Medical Concepts Inc. has demonstrated a year-over-year increase of 7.0% in active surgeon users, totaling approximately 3,285, which reflects a solid foundation for growth despite a slight decline in utilization per surgeon. The company has strategically expanded its product offerings beyond the Lapiplasty system to address the competitive landscape, creating opportunities for modest revenue growth and improved margins through higher average selling prices and increased market share in complementary procedures. Additionally, the enhancement of the sales force and initiatives to boost direct-to-consumer programs, physician education, and sales rep hiring are positioned to capitalize on the anticipated recovery of the bunion market, providing a positive outlook for Treace Medical Concepts's financial performance.
Bears say
Treace Medical Concepts Inc. is facing a challenging financial outlook, as projected revenue for the fourth quarter is anticipated to decline by approximately 10% year-over-year to $61.8 million, despite traditionally being a peak period for bunion procedures. The company's revenue guidance for FY25 has been revised down from $224-230 million to $211-213 million, primarily due to headwinds related to lapiplasty and a slowdown in elective surgeries, leading to further concerns about the sustainability of its growth. Additionally, customer feedback indicates an average decline in bunion procedure volumes of around 7% year-over-year, suggesting ongoing pressure on the company's market demand and future revenue potential.
This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.
TMCI Analyst Forecast & Price Prediction
Start investing in TMCI
Order type
Buy in
Order amount
Est. shares
0 shares